相关实验视频

Updated: Jan 16, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

用纳米技术准PI3K/Akt/mTOR通路:一种针对胃肠道癌症的新治疗策略

Maryam Kaviani¹, Vahid Tayebi-Khorrami², Yegane Marami¹

¹Student Research Committee, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran.

Nanomedicine : nanotechnology, biology, and medicine

|September 28, 2025

概括

纳米技术通过向PI3K/Akt/mTOR途径,为胃肠癌提供创新的治疗方法. 基于纳米粒子的疗法在提高治疗效率和减少副作用方面显示出有前途.

科学领域:

在瘤学瘤学.
生物技术是生物技术.
材料科学材料科学材料科学

背景情况:

胃肠道 (GI) 癌症是全球癌症死亡的主要原因.
拉巴胺素 (mTOR) 途径的酸化物3-激酶 (PI3K) /Akt/哺乳动物标在肠道癌症的进展,生存和耐药性方面至关重要.
目前用于胃肠道癌的化疗面临诸多挑战,包括药物耐药性和显著的副作用.

研究的目的:

审查PI3K/Akt/mTOR途径在胃肠道恶性瘤中的作用.
探索基于纳米粒子的治疗策略,针对肠道癌症中这种途径.
讨论基于纳米粒子的癌症治疗的最新进展,挑战和未来前景.

主要方法:

对GI癌症中的PI3K/Akt/mTOR途径的文献综述.
探索各种纳米粒子分类,包括基于金属的,基于脂质的和聚合物纳米粒子.
对针对性治疗的超小纳米粒子和超级粒子的研究进行讨论.

主要成果:

基于纳米粒子的方法可以提高针对PI3K/Akt/mTOR途径的疗法的精度和有效性.
不同类型的纳米粒子 (金属,脂质,聚合物) 提供不同的治疗潜力.
最近的研究强调了超小纳米粒子和超级粒子在癌症治疗中的重要性.

结论:

纳米技术为克服当前胃肠癌治疗方法的局限性提供了一个有希望的途径.
用纳米粒子向PI3K/Akt/mTOR通路可以提高治疗结果,同时最大限度地减少不良影响.
对纳米粒子设计和应用的进一步研究为推进胃肠道癌症治疗提供了显著的潜力.

关键词:

标签: 活动活动活动胃肠道的癌症胃肠道的癌症纳米技术纳米技术在PI3K中,PI3K是指PI3K.在mTOROR中使用mTOR.

更多相关视频

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...